Back to resultsExpanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Primary Purpose
Aplastic Anemia
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Iticitinib
Sponsored by
About this trial
This is an expanded access trial for Aplastic Anemia
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03906318
Brief Title
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Official Title
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Study Type
Expanded Access
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation
4. Oversight
5. Study Description
Brief Summary
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aplastic Anemia
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Iticitinib
10. Eligibility
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Forbes Satter, MD
Organizational Affiliation
Baylor College of Medicine - Texas Children's Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
35590143
Citation
Rosenberg JM, Peters JM, Hughes T, Lareau CA, Ludwig LS, Massoth LR, Austin-Tse C, Rehm HL, Bryson B, Chen YB, Regev A, Shalek AK, Fortune SM, Sykes DB. JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. Med. 2022 Jan 14;3(1):42-57.e5. doi: 10.1016/j.medj.2021.12.003.
Results Reference
derived
Learn more about this trial
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
We'll reach out to this number within 24 hrs